Ruxolitinib cream for Hand Eczema (TRuE-CHE2 Trial)

"Currently, patients are being enrolled for this clinical trial at Onsite Clinical Solutions, Llc Charlotte Central Office in Charlotte, North carolina, Delright Research in Tampa, Florida, and Forcare Clinical Research in Plainfield, Indiana. There are also 16 other potential sites for enrollment."

"Yes, this is an ongoing study that is currently looking for participants. The clinical trial was originally posted on 1/31/2023 and was last edited on 10/17/2022. The trial is looking for 180 patients at 16 sites."

"Ruxolitinib cream's safety is rated a 3. This is because there is some clinical data supporting its efficacy and multiple rounds of data supporting its safety."

"This clinical trial includes patients aged 18 to 99. There are 84 other trials for patients under 18 and 118 for those 65 and older."

"Indeed, the listing on clinicaltrials.gov contains information indicating that the trial is presently looking for subjects. The trial was first posted on 1/31/2023 and has since been edited on 10/17/2022. The trial is set to enroll 180 individuals from 16 different sites."

"This clinical trial is admitting 180 participants, within the ages of 18 and 99 who have eczema. It is important that patients also meet the following criteria: Screening and baseline IGA-CHE 3 or 4., Recent history (within the past 1 year of baseline) of inadequate response to treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), or oral alitretinoin; or intolerance or contraindication to TCS or TCI or oral alitretinoin., Willingness to avoid pregnancy or fathering children based on the criteria below.,"